Thermo Fisher Scientific to Acquire Solventum’s Purification and Filtration Business

Thermo Fisher Scientific Expands Bioprocessing Capabilities with $4.1 Billion Acquisition of Solventum’s Purification & Filtration Business

Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a definitive agreement to acquire Solventum’s Purification & Filtration business for $4.1 billion in cash. This strategic acquisition enhances Thermo Fisher’s bioproduction portfolio, particularly in purification and filtration technologies crucial for biologics manufacturing, medical technologies, and industrial applications.

Strengthening Bioprocessing Capabilities

Solventum’s Purification & Filtration business is a globally recognized provider of advanced purification and filtration solutions. Operating across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, the business employs approximately 2,500 professionals and generated $1 billion in revenue in 2024.

The acquisition aligns closely with Thermo Fisher’s existing leadership in bioproduction, particularly in cell culture media and single-use technologies. The integration of Solventum’s filtration portfolio strengthens Thermo Fisher’s upstream and downstream biologics manufacturing capabilities, making it a more comprehensive partner for biopharmaceutical and biotechnology companies.

Industry Impact and Strategic Synergy

The combination of Solventum’s innovative purification and filtration technologies with Thermo Fisher’s bioproduction expertise is expected to enhance efficiencies in biologics development and manufacturing. The expansion of Thermo Fisher’s bioprocessing portfolio will support drug developers in optimizing production workflows, reducing contamination risks, and improving scalability for biologic therapies.

Marc N. Casper, chairman, president, and CEO of Thermo Fisher, highlighted the strategic importance of this acquisition:

“The addition of Solventum’s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders. Solventum’s portfolio of solutions will be valued by our customers, and further demonstrate our disciplined capital deployment strategy which has an excellent track record of creating shareholder value.”

He further emphasized the impact on the bioprocessing sector, stating:

“As the trusted partner to our customers, Solventum’s Purification & Filtration business will expand and add differentiated capabilities to our bioprocessing portfolio to better serve our customers in this rapidly growing market. We look forward to welcoming our new colleagues to Thermo Fisher.”

Regulatory Approvals and Future Integration

The $4.1 billion transaction is expected to close by the end of 2025, subject to customary regulatory approvals and closing conditions. Once finalized, Solventum’s Purification & Filtration business will be integrated into Thermo Fisher’s Life Sciences Solutions segment, further strengthening its leadership in bioprocessing solutions.

With growing demand for biologics and next-generation therapies, this acquisition reinforces Thermo Fisher’s commitment to delivering cutting-edge bioprocessing technologies that support faster, more efficient, and scalable biologics production.